Anti-c1s antibodies and methods of use thereof
AssigneeBioverativ USA Inc.
InventorsSandip Panicker, Graham Parry, Nancy E. Stagliano
Life of this patent
Estimating the term…
Abstract
The present disclosure provides antibodies that specifically bind complement pathway component C1s. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the anti-C1s antibodies; and host cells comprising the nucleic acids. The present disclosure provides compositions comprising the anti-C1s antibodies. The present disclosure provides methods of use of the anti-C1s antibodies.
Claims20
An antibody, comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable (VH) region and a heavy chain constant region, and the light chain comprises a light chain variable (VL) region;
- wherein the VL region comprises a VL complementary determining region (CDR) 1, a VL CDR2, and a VL CDR3, and wherein the VH region comprises a VH CDR1, a VH CDR2, and a VH CDR3;
- wherein the VL CDR1 comprises SEQ ID NO:
- 1;
- wherein the VL CDR2 comprises SEQ ID NO:
- 2;
- wherein the VL CDR3 comprises SEQ ID NO:
- 3;
- wherein the VH CDR1 comprises SEQ ID NO:
- 4;
- wherein the VH CDR2 comprises SEQ ID NO:
- 5;
- wherein the VH CDR3 comprises SEQ ID NO:
- 6;
- wherein the heavy chain constant region comprises an IgG4 constant region, wherein amino acid residue 308 of the heavy chain constant region corresponding to SEQ ID NO:
- 28 is Leu, and amino acid residue 314 of the heavy chain constant region corresponding to SEQ ID NO:
- 28 is Ser;
- and wherein the antibody specifically binds activated C1s.
An antibody, comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable (VH) region and a heavy chain constant region, and the light chain comprises a light chain variable (VL) region;
- wherein the VL region comprises a VL complementary determining region (CDR) 1, a VL CDR2, and a VL CDR3, and wherein the VH region comprises a VH CDR1, a VH CDR2, and a VH CDR3;
- wherein the VL CDR1 comprises SEQ ID NO:
- 1;
- wherein the VL CDR2 comprises SEQ ID NO:
- 2;
- wherein the VL CDR3 comprises SEQ ID NO:
- 3;
- wherein the VH CDR1 comprises SEQ ID NO:
- 4;
- wherein the VH CDR2 comprises SEQ ID NO:
- 5;
- wherein the VH CDR3 comprises SEQ ID NO:
- 6;
- wherein the heavy chain constant region comprises SEQ ID NO:
- 28;
- and wherein the antibody specifically binds activated C1s.
Dependencies are inferred from the claim text.